Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, a global leader in cell-free DNA and genetic testing, will present at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for Thursday, May 30, 2024, at 8:40 a.m. PT (11:40 a.m. ET). The event will be live-streamed on the investor relations section of Natera's website, with a replay available shortly after.
Natera (NASDAQ: NTRA) will present new data at the 2024 ASCO Annual Meeting, May 31 – June 4, 2024. The data spans multiple cancer types, including breast, colorectal (CRC), lung, melanoma, esophageal, and urothelial cancers. Natera's Signatera™ and Empower™ tests will be highlighted in one oral and 13 poster presentations. Key studies include the CIRCULATE-Japan GALAXY study, showcasing the prognostic and predictive utility of Signatera for CRC. Natera expects topline results from the ALTAIR phase III trial by August 2024. Presentations will demonstrate ctDNA's role in detecting minimal residual disease and monitoring treatment responses in various cancers.
Natera, Inc. (NASDAQ: NTRA) reported positive first quarter financial results for 2024, with $367.7 million in total revenues, a 52.1% increase from the previous year. The company achieved a gross margin of 56.7%, processed 735,800 tests, and had a net loss of $67.6 million. Natera expects total revenue of $1.42 billion to $1.45 billion for 2024.
Natera, Inc. announced a new publication in JCO Precision Oncology showcasing the effectiveness of its Signatera test in detecting breast cancer recurrence early. The study involved 156 early-stage breast cancer patients followed for up to 12 years post-surgery. Signatera detected relapse 38 months earlier than imaging, with an 88.2% sensitivity rate. Patients testing positive for ctDNA had worse survival outcomes. The study emphasizes the importance of early recurrence detection and long-term monitoring in breast cancer patients.
Natera, Inc. (NASDAQ: NTRA) will report its first quarter 2024 results on May 9. The company is a global leader in cell-free DNA and genetic testing. The earnings conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Natera, Inc. (NASDAQ: NTRA) has launched a new cfDNA-based fetal RhD test to support Ob/Gyn physicians and patients during a nationwide shortage of RhIg therapy. The test offers 100% sensitivity and >99% specificity, and can be conducted as early as nine weeks gestation. This initiative is important to prevent complications from alloimmunization in pregnancies where the maternal blood type is RhD-negative and the fetal blood type is RhD-positive. The product launch was supported by a large clinical validation study with over 650 patients, demonstrating Natera's commitment to accurate and reliable diagnostics in women's health.
Summary not available.
Summary not available.
Summary not available.
Summary not available.